WPRIM Management System> DCMS> Osteoporosis and Sarcopenia> 2017> 3> 1

Volume: 3 Issue: 1

1. Denosumab for the treatment of osteoporosis. Page:8—17
2. An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015. Page:1—7
3. Response to the Editor. Page:60—61
4. Letter to the Editor. Page:59—59
5. Associations between serum 25-hydroxyvitamin D3 level and skeletal muscle mass and lower limb muscle strength in Japanese middle-aged subjects. Page:53—58
6. Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change. Page:45—52
7. Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study. Page:37—44
8. Favorable effects of skeletal muscle on bone are distinguished according to gender and skeletal sites. Page:32—36
9. Osteoporosis prevention and osteoporosis exercise in community-based public health programs. Page:18—31

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.